Seedlabs

SUD-Screened Stimulant Therapy: Prescribing-Safety Module for Adult ADHD Clinics

A screening process for ADHD clinics to find and manage drug addiction risks in adult patients.

A standardized substance-use screening and monitoring workflow built into adult ADHD stimulant prescribing, so the most common and riskiest adult comorbidity is caught and managed during treatment.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderAdult psychiatry and telehealth prescribing safety / controlled-substance risk management

Concept

A prescribing-safety module for adult ADHD clinics and telehealth prescribers: every patient starting or continuing stimulant therapy completes a standardized, validated substance-use screen at initiation and at set intervals (e.g., quarterly), with screen results, prescription-drug-monitoring (PDMP) review, and risk tier documented in a single workflow. Patients screening positive are auto-routed to a defined pathway — SUD-informed prescribing, a non-stimulant alternative such as atomoxetine, or addiction-medicine referral — rather than ad-hoc clinician judgment. Sold as a compliance and safety layer to the growing base of adult ADHD prescribers.

Why now

A systematic review of 32 studies shows substance use disorder is the most frequent psychiatric comorbidity in adults with ADHD — 10.0–82.9% in clinical populations versus 2.3–41.2% in general populations — with mood, anxiety, and personality disorders also elevated, and it explicitly calls for standardized diagnostic instruments [3]. Simultaneously, the European ADHD Guidelines Group finds amphetamines are the most effective pharmacotherapy for adults [4], and the pharmacological review confirms stimulants as first-line with large short-term effect sizes [2], so the adult stimulant-treated population keeps expanding — 15.5 million US adults (6.0%) already reported a current ADHD diagnosis in 2023, with telehealth accelerating access [8]. A high-prevalence, high-risk comorbidity meeting rapidly growing controlled-substance prescribing, with no standardized screening standard in between, is a safety gap this product closes.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 4 papers90

A high-utility compliance and safety tool that addresses a critical clinical gap in the rapidly expanding adult ADHD telehealth market.

Evidence strength
5/5
The idea is directly supported by a systematic review showing extremely high SUD comorbidity rates (up to 82.9%) and a clear call for standardized diagnostic instruments.
Market pull
5/5
Telehealth ADHD clinics face immense regulatory and liability pressure regarding controlled substances, making a standardized safety module a high-priority purchase.
Novelty & moat
3/5
While similar to the 'Symptom Attribution Tool', this shifts the focus from initial diagnosis to ongoing prescribing safety and longitudinal monitoring for adults.
Feasibility
5/5
The MVP is a straightforward digital workflow integrating existing validated screens and PDMP API calls, requiring minimal R&D.
Wedge clarity
4/5
The wedge is a specific 'prescribing-safety module' for a defined user (adult ADHD prescribers) with a clear trigger (stimulant initiation/renewal).
Simplicity / focus
5/5
The product is a single, focused workflow rather than an over-scoped platform, focusing exclusively on the SUD-stimulant risk intersection.

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Talkiatrycompany

    The psychiatry telehealth platform carries a large adult ADHD caseload; standardized SUD screening and documentation reduces clinical and regulatory risk around stimulant prescribing at scale.

  • ADHD 360company

    The UK adult ADHD provider could embed the SUD screen as a defensible, auditable safety layer in its stimulant prescribing pathway.

  • Fridacompany

    The Canadian adult ADHD telehealth clinic could add the monitoring module to its pharmacotherapy offering, strengthening safety for patients on long-term stimulants.

  • American Society of Addiction Medicineorganization

    ASAM could endorse or co-develop an integrated SUD-screening standard for ADHD prescribers, extending its mission into a high-prevalence but under-screened population.

Research it builds on

  1. Evidence-based pharmacological treatment options for ADHD in children and adolescents
    Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann et al. · 2021 · 296 citations
    All ideas from this paper →
  2. The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review
    Won-Seok Choi, Young Sup Woo, Sheng‐Min Wang et al. · 2022 · 211 citations
    All ideas from this paper →
  3. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)
    David Coghill, Tobias Banaschewski, Samuele Cortese et al. · 2021 · 178 citations
    All ideas from this paper →
  4. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023
    Brooke S. Staley, Lara R. Robinson, Angelika Hartl Claussen et al. · 2024 · 87 citations
    All ideas from this paper →
Leave feedback
feasibility